- « Previous Releases | Next Releases »
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc.(NASDAQ: BCRX) today announced that its fourth quarter and full year 2011 financial results will be released on Thursday, February 16, 2012. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Timeto discuss the financial results and to provide an update on the Company's programs. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Thomas R. Staab, II, Senior Vice President and Chief Financial Officer and Dr. William P. Sheridan, Senior Vice President and Chief Medical Officer.
The webcast can be accessed by logging onto www.BioCryst.com. Please connect to the website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed. To participate in the conference call, please dial 1-877-303-8027 (
United States) or 1-760-536-5165 (International). No passcode is needed for the call. The audio portion of the webcast will be archived and available for replay for at least 14 days.
BioCryst Pharmaceuticalsdesigns, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases and cancer. BioCryst currently has three novel late-stage compounds in development: peramivir, a neuraminidase inhibitor for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout, and forodesine, an orally-available PNP inhibitor for cancer, which is being developed by Mundipharmaunder a global license agreement. Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through preclinical and early development to address the unmet medical needs of patients and physicians. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the
SECand located at http://investor.shareholder.com/biocryst/sec.cfm.
BioCryst Pharmaceuticals Robert Bennett, 919-859-7910
News Provided by Acquire Media